FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia
- 1 May 2004
- journal article
- review article
- Published by S. Karger AG in Acta Haematologica
- Vol. 112 (1-2) , 68-78
- https://doi.org/10.1159/000077561
Abstract
Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the prognostically intermediate group. This group is supposed to be a mixed group of AML with differences in the underlying pathogenesis. For more individualized treatment options it would be helpful to better characterize this large AML group not only by molecular mutations but also use these markers for the definition of minimal residual disease (MRD). However, so far the cytogenetically intermediate AML has been lacking suitable markers for PCR-based MRD detection like the fusion genes in the prognostically favourable subgroups. The suitability of the FLT3-LM as a target for PCR-based MRD was discussed controversially as it seemed to be a rather unstable marker. Thus, we aimed at the evaluation of FLT3-LM as a marker for residual disease in a large cohort of AML. Paired samples of 97 patients with AML at diagnosis and at relapse were analyzed. It could be shown that in only four cases a loss of the length mutation was detected. This is in the range of other well-characterized AML relapsing with a different geno- and/or phenotype. In contrast, a change in the ratio of the mutated allele in comparison to the wild-type allele was frequently observed. In detail, the FLT3-LM showed a tendency to accumulate during disease progression and was found more frequently at relapse than at diagnosis. In addition, 45 patients were analyzed at different time points during and after therapy. Using conventional PCR it clearly could be shown that for most of the patients positive at presentation FLT3-LM is a reliable PCR marker for monitoring treatment response. Even an early detection of relapse was possible in some cases.Keywords
This publication has 22 references indexed in Scilit:
- New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcriptsBlood, 2003
- Flt3 mutations and leukaemiaBritish Journal of Haematology, 2003
- Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialBlood, 2003
- Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapseBlood, 2002
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Acute Myelogenous Leukemia with Internal Tandem Duplication of the Flt3 Gene Appearing or Altering at the Time of Relapse: A Report of Two CasesLeukemia & Lymphoma, 2002
- Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemiaLeukemia, 2001
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Detection and quantification ofCBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCRGenes, Chromosomes and Cancer, 2001
- A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populationsCell, 1991